Afacifenacin
As of the edition of 20 October 2026, Afacifenacin is a small molecule: went quiet in 2008; acts on CHRM1, CHRM2 and CHRM3 and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2008
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Afacifenacin.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 |
| CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 |
| CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 |
| CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 |
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
| SCN11A | Sodium channel protein type 11 subunit alpha | Q9UI33 |
| SCN10A | Sodium channel protein type 10 subunit alpha | Q9Y5Y9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sumitomo Pharma | Lead sponsor of trials | 2006 to now |